Journal of Obstetric and Gynaecological Practices POGS

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  3 (2025)
Volume  2 (2024)
Volume  1 (2023)
Related articles

VOLUME 3 , ISSUE 1 ( January-June, 2025 ) > List of Articles

REVIEW ARTICLE

Urinary Tract Infection: A Multimodal Approach to Management

Arif Ahmed Faruqui

Keywords : Antibiotic, Cranberry, D-Mannose, Nonantibiotic, Probiotics, Recurrence

Citation Information : Faruqui AA. Urinary Tract Infection: A Multimodal Approach to Management. J Obstet Gynaecol 2025; 3 (1):42-48.

DOI: 10.5005/jogyp-11012-0045

License: CC BY-NC 4.0

Published Online: 12-02-2025

Copyright Statement:  Copyright © 2025; The Author(s).


Abstract

Urinary tract infections (UTIs) are highly prevalent, resulting in 7 million outpatient visits, 1 million emergency department visits, and 100,000 hospitalizations annually. They predominantly affect females aged 20–50. Antibiotics are the primary treatment, but about 30% of treated females experience recurrence (rUTI). Regular antibiotic use also increases the risk of antibiotic resistance and side effects. Moreover, antibiotics can cause dysbiosis of the intestinal and vaginal flora, increasing the risk of recurrence. Therefore, nonantibiotic treatments are worth considering reducing antibiotic use and side effects. Nonantibiotic options such as cranberry juice, D-mannose, probiotics, and potassium magnesium citrate can alleviate UTI symptoms and reduce recurrence risk. Studies indicate that combining these non-antibiotic treatments, which work through different mechanisms, leads to better clinical outcomes. This review explores the role of each non- antibiotic treatment, the rationale for their combination, and supports their effectiveness with clinical evidence. Thus, the combination of non-antibiotic treatments may provide a better outcome for patients with UTI and rUTI.

PDF Share
  1. Mohapatra S, Panigrahy R, Tak V, et al. Prevalence and resistance pattern of uropathogens from community settings of different regions: An experience from India. Access Microbiol 2022;4(2):000321. DOI: 10.1099/acmi.0.000321.
  2. Pujades-Rodriguez M, West RM, Wilcox MH, et al. Lower urinary tract infections: Management, outcomes and risk factors for antibiotic re-prescription in primary care. EClinicalMedicine 2019;14:23–31. DOI: 10.1016/j.eclinm.2019.07.012.
  3. Walter Bushnell Healthcare Foundation. Resistance Pattern in UTI: Indian and International Perspectives. [online] Available from: https://wbhf.walterbushnell.com/publications/bush-beats/item/67-resistance-pattern-in-uti-indian-and-international-perspectives#. [Last accessed November, 2024].
  4. Flores-Mireles AL, Walker JN, Caparon M, et al. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015;13(5):269–284. DOI: 10.1038/nrmicro3432.
  5. Hannan TJ, Totsika M, Mansfield KJ, et al. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev 2012;36(3):616–648. DOI: 10.1111/j.1574-6976.2012.00339.x.
  6. Abou Heidar NF, Degheili JA, Yacoubian AA, et al. Management of urinary tract infection in women: A practical approach for everyday practice. Urol Ann 2019;11(4):339–346. DOI: 10.4103/UA.UA_104_19.
  7. Jancel T, Dudas V. Management of uncomplicated urinary tract infections. West J Med 2002;176(1):51–55. DOI: 10.1136/ewjm. 176.1.51.
  8. Aggarwal N, Leslie SW, Lotfollahzadeh S. Recurrent Urinary Tract Infections. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. [online] Available from: https://www.ncbi.nlm.nih.gov/books/NBK557479/. [Last accessed November, 2024].
  9. Amawi HA, U'wais HT, Nusair MB, et al. Management of urinary tract infections and antibiotic susceptibility patterns of bacterial isolates. Int J Clin Pract 2021;75(10):e14475. DOI: 10.1111/ijcp.14475.
  10. WebMD. Antibiotics for UTI Treatment. [online] Available from: https://www.webmd.com/a-to-z-guides/what-are-antibiotics-for-uti. [Last accessed November, 2024].
  11. Sabih A, Leslie SW. Complicated Urinary Tract Infections. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. [online] Available from: https://www.ncbi.nlm.nih.gov/books/NBK436013/. [Last accessed November, 2024].
  12. Kenneally C, Murphy CP, Sleator RD, et al. The urinary microbiome and biological therapeutics: Novel therapies for urinary tract infections. Microbiol Res 2022;259:127010. DOI: 10.1016/j.micres.2022.127010.
  13. Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: How promising is the use of probiotics?. Indian J Med Microbiol 2017;35(3):347–354. DOI: 10.4103/ijmm.IJMM_16_292.
  14. Sihra N, Goodman A, Zakri R, et al. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol 2018;15(12):750–776. DOI: 10.1038/s41585-018-0106-x.
  15. Raz R, Chazan B, Dan M. Cranberry juice and urinary tract infection. Harefuah 143(12):891–894, 909. PMID: 15666710.
  16. Lynch DM. Cranberry for prevention of urinary tract infections. Am Fam Physician 2004;70(11):2175–2177. PMID: 15606066.
  17. Ofek I, Beachey EH. Mannose binding and epithelial cell adherence of Escherichia coli. Infect Immun 1978;22(1):247–254. DOI: 10.1128/iai.22.1.247-254.1978.
  18. Hisano M, Bruschini H, Nicodemo AC, et al. Cranberries and lower urinary tract infection prevention. Clinics (Sao Paulo) 2012;67(6):661–668. DOI: 10.6061/clinics/2012(06)18.
  19. Hidalgo G, Chan M, Tufenkji N. Inhibition of Escherichia coli CFT073 fliC expression and motility by cranberry materials. Appl Environ Microbiol 2011;77(19):6852–6857. DOI: 10.1128/AEM.05561-11.
  20. O'May C, Tufenkji N. The swarming motility of Pseudomonas aeruginosa is blocked by cranberry proanthocyanidins and other tannin-containing materials. Appl Environ Microbiol 2011;77(9):3061–3067. DOI: 10.1128/AEM.02677-10.
  21. Howell AB, Reed JD, Krueger CG, et al. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Phytochemistry 2005;66(18):2281–2291. DOI: 10.1016/j.phytochem.2005.05.022.
  22. Liu Y, Black MA, Caron L, et al. Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of Escherichia coli. Biotechnol Bioeng 2006;93(2):297–305. DOI: 10.1002/bit.20675.
  23. Ren D, Zuo R, González Barrios AF, et al. Differential gene expression for investigation of Escherichia coli biofilm inhibition by plant extract ursolic acid. Appl Environ Microbiol 2005;71(7):4022–4034. DOI: 10.1128/AEM.71.7.4022-4034.2005.
  24. Davis JA, Freeze HH. Studies of mannose metabolism and effects of long-term mannose ingestion in the mouse. Biochim Biophys Acta 2001;1528(2–3):116–126. DOI: 10.1016/s0304-4165(01)00183-0.
  25. Fettweis JM, Brooks JP, Serrano MG, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology (Reading) 2014;160(Pt 10):2272–2282. DOI: 10.1099/mic.0.081034-0.
  26. Fronzes R, Remaut H, Waksman G. Architectures and biogenesis of non-flagellar protein appendages in Gram-negative bacteria. EMBO J 2008;27(17):2271–2280. DOI: 10.1038/emboj.2008.155.
  27. Mydock-McGrane LK, Cusumano ZT, Janetka JW. Mannose-derived FimH antagonists: A promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease. Expert Opin Ther Pat 2016;26(2):175–197. DOI: 10.1517/13543776.2016.1131266.
  28. Michaels EK, Chmiel JS, Plotkin BJ, et al. Effect of D-mannose and D-glucose on Escherichia coli bacteriuria in rats. Urol Res 1983;11(2):97–102. DOI: 10.1007/BF00256954.
  29. Schaeffer AJ, Chmiel JS, Duncan JL, et al. Mannose-sensitive adherence of Escherichia coli to epithelial cells from women with recurrent urinary tract infections. J Urol 1984;131(5):906–910. DOI: 10.1016/s0022-5347(17)50706-5.
  30. Velraeds MM, van der Mei HC, Reid G, et al. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl Environ Microbiol 1996;62(6):1958–1963. DOI: 10.1128/aem.62.6.1958-1963.1996.
  31. Andreu A, Stapleton AE, Fennell CL, et al. Hemagglutination, adherence, and surface properties of vaginal Lactobacillus species. J Infect Dis 1995;171(5):1237–1243. DOI: 10.1093/infdis/171.5. 1237.
  32. Osset J, Bartolomé RM, García E, etal. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis 2001;183(3):485–491. DOI: 10.1086/318070.
  33. Mastromarino P, Brigidi P, Macchia S, et al. Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets. J Appl Microbiol 2002;93(5):884–893. DOI: 10.1046/j.1365-2672.2002.01759.x.
  34. Barrons R, Tassone D. Use of lactobacillus probiotics for bacterial genitourinary infections in women: A review. Clin Ther 2008;30(3):453–468. DOI: 10.1016/j.clinthera.2008.03.013.
  35. Zárate G, Nader-Macias ME. Influence of probiotic vaginal lactobacilli on in vitro adhesion of urogenital pathogens to vaginal epithelial cells. Lett Appl Microbiol 2006;43(2):174–180. DOI: 10.1111/j.1472-765X.2006.01934.x.
  36. Manzoor A, Ul-Haq I, Baig S, et al. Efficacy of locally isolated lactic acid bacteria against antibiotic-resistant uropathogens. Jundishapur J Microbiol 2016;9(1):e18952. DOI: 10.5812/jjm.18952.
  37. Shim YH, Lee SJ, Lee JW. Antimicrobial activity of lactobacillus strains against uropathogens. Pediatr Int 2016;58(10):1009–1013. DOI: 10.1111/ped.12949.
  38. Beerepoot MA, ter Riet G, Nys S, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: A randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012;172(9):704–712. DOI: 10.1001/archinternmed.2012.777.
  39. Mehta P, Leslie SW, Reddivari AKR. Dysuria. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. [online] Available from: https://www.ncbi.nlm.nih.gov/books/NBK549918/. [Last accessed November, 2024].
  40. Wrenn K. Dysuria, Frequency, and Urgency. In: Walker HK, Hall WD, Hurst JW (Eds). Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. [online] Chapter 181. Available from: https://www.ncbi.nlm.nih.gov/books/NBK291/. [Last accessed November, 2024].
  41. O'Kane DB, Dave SK, Gore N, et al. Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2016;4(4):CD010745. DOI: 10.1002/14651858.CD010745.pub2.
  42. EMC. Potassium citrate mixture. [online] Available from: https://www.medicines.org.uk/emc/landing?status=1#gref. [Last accessed November, 2024].
  43. Gupta K, Chou MY, Howell A, et al. Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. J Urol 2007;177(6):2357–2360. DOI: 10.1016/j.juro.2007.01.114.
  44. Howell AB, Vorsa N, Der Marderosian A, et al. Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. N Engl J Med 1998;339(15):1085–1086. DOI: 10.1056/NEJM199810083391516.
  45. Rădulescu D, David C, Turcu FL, et al. Combination of cranberry extract and D-mannose – possible enhancer of uropathogen sensitivity to antibiotics in acute therapy of urinary tract infections: Results of a pilot study. Exp Ther Med 2020;20(4):3399–3406. DOI: 10.3892/etm.2020.8970.
  46. Vicariotto F. Effectiveness of an association of a cranberry dry extract, D-mannose, and the two microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in women affected by cystitis: A pilot study. J Clin Gastroenterol 2014;48 Suppl 1:S96–S101. DOI: 10.1097/MCG.0000000000000224.
  47. Pugliese D, Acampora A, Porreca A, et al. Effectiveness of a novel oral combination of D-Mannose, pomegranate extract, prebiotics and probiotics in the treatment of acute cystitis in women. Arch Ital Urol Androl 2020;92(1):34–38. DOI: 10.4081/aiua. 2020.1.34.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.